Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium selenate for drug-resistant mesial temporal lobe epilepsy
ACTRN12623000446662Phase 2Recruiting
- Sponsor
- Alfred Health
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mesial temporal lobe epilepsy (MTLE) and temporal lobe epilepsy (TLE) comparing Sodium selenate with Placebo (2 arms). Primary endpoint: Change in desirability of outcome (DOOR) score between active and placebo groups. Started Apr 2024; status: recruiting.
02
Drugs
sodium selenate
03
Conditions
mesial temporal lobe epilepsy (MTLE)temporal lobe epilepsy (TLE)
Beyond the preview
Go deeper on ACTRN12623000446662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000446662.